REGiMMUNE Limited.
Update：2025/12/24
Industries
Main Industry
Health Care
Main Product/Service
REGiMMUNE’s lead product candidate is RGI-2001, a liposomal small-molecule agent designed to expand regulatory T cells for the prevention of acute graft-versus-host disease (aGvHD). The company also is developing antibody and cell-therapy candidates to ei
Founded Year
2018
Unified Business No.
50779876
Status
Active
Number of Employees
0
Total Paid-in
Capital
240,962,510 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Exclusive content for members
Members-only content. Please log in to access.
Introduction
REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies by harnessing the power of regulatory T cells (Tregs). Their mission is: “Delivering breakthrough immune medicines by harnessing the power of regulatory
